View all the latest information in acute lymphoblastic leukemia, arranged by trials and clinical studies. Listed below are recently added trial updates.
Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL
Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two...
BALLI-01 Study: Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to...
Phase I results show venetoclax and navitoclax combination is tolerable and associated with responses in pediatric patients with R/R ALL and LL
The prognosis is poor for pediatric patients with...
Venetoclax and navitoclax for R/R ALL and lymphoblastic lymphoma
During the 2020 European Hematology Association (EHA) Annual Congress, our ALL Hub Steering Committee member, Elias Jabbour, presented...
Current recommendations for therapy-related toxicity management in ALL
Despite the great clinical advances in the field of acute lymphoblastic leukemia (ALL), novel therapies have led to the emergence...
The current treatment landscape of acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a rare hematological disorder with a bimodal incidence in childhood and in older adults. The...
Old and new ADCs for the treatment of ALL and AML
Since the beginning of their development in the early 1980s, a lot of progress has been made in the development of monoclonal antibodies (mAbs) for...
The effect of inotuzumab ozogamicin treatment exposure and cycles on R/R ALL outcomes
Inotuzumab ozogamicin (InO) is an anti‐CD22 monoclonal antibody conjugated to calicheamicin that has been...
AIEOP-BFM ALL 2000
BMT CTN 1101
MRC UKALLXII/ECOG E2993
SJCRH Total Therapy 16